About: Recombinant Plant Engineering for Immunotherapeutic Production

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant Plant Engineering for Immunotherapeutic Production Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recombinant Plant Engineering for Immunotherapeutic Production
Creator	Singh, Neetu Kaur, Gurminder Praveen, & Saxena, Gauri Singh, Ankit Singh, Sanchita Verma, C
topic	covid:a18c85c2b16eab20779da0d0d870f94e5b94b23c#this
Source	Medline; PMC
abstract	PURPOSE OF REVIEW: The requirement for large quantities of therapeutic proteins has fueled a great interest in the production of recombinant proteins in plant bioreactors. The vaccines and bio-therapeutic protein production in plants hold the promise of significantly lowering the cost of manufacturing life-saving drugs. This review will reflect the current status and challenges that the molecular farming platform faces becoming a strategic solution for the development of low-cost bio-therapeutics for developing countries. RECENT FINDINGS: Different plant parts have been successfully identified as suitable expression systems for the commercial production of therapeutic proteins for some human and animal diseases ranging from common cold to AIDS. The processed therapeutics from such sources are devoid of any toxic components. The large-scale cultivation of these transgenic plants would be possible anywhere in the world including developing countries, which lack sophisticated drug manufacturing units. A couple of such commercially generated products have already hit the market with success. Newer methods using suitable plant viruses and recombinant gene expression systems have already been devised for producing therapeutic proteins and peptides. SUMMARY: Plants are promising bio-factories for therapeutic protein production because of their several advantages over the other expression systems especially the advanced mechanisms for protein synthesis and post-translational modification which are very much similar to animal cells. Plant biotechnologists are much attracted to the bio-farming because of its flexibility, scalability, low manufacturing cost, as well as the lack of risk of toxic or pathogenic contamination. A number of projects on bio-farming are designed and are at various developmental stages but have not yet become available to the pharmaceutical industry. Therefore, we need further advancement in the optimization of lab protocols for up-scaling the production of such therapeutics at commercial level with a promise to offer their best clinical use.
has issue date	2017-10-16(xsd:dateTime)
bibo:doi	10.1007/s40610-017-0078-2
bibo:pmid	32226727
has license	no-cc
sha1sum (hex)	a18c85c2b16eab20779da0d0d870f94e5b94b23c
schema:url	https://doi.org/10.1007/s40610-017-0078-2
resource representing a document's title	Recombinant Plant Engineering for Immunotherapeutic Production
has PubMed Central identifier	PMC7099902
has PubMed identifier	32226727
schema:publication	Curr Mol Biol Rep
resource representing a document's body	covid:a18c85c2b16eab20779da0d0d870f94e5b94b23c#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/a18c85c2b16eab20779da0d0d870f94e5b94b23c
is schema:about of	named entity 'identified' named entity 'advanced' named entity 'protein' named entity 'toxic' named entity 'Purpose' named entity 'market' named entity 'number' named entity 'platform' named entity 'promise' named entity 'ROONEY' named entity 'AGRICULTURAL PRODUCTION' named entity 'DRUG' named entity 'COUPLE' named entity 'EXPRESSION' named entity 'PROCESSED' named entity 'DIFFERENT' named entity 'HIT' named entity 'SUCCESS' named entity 'PURPOSE' named entity 'WORLD' named entity 'FACES' named entity 'COST' named entity 'NEED' named entity 'REQUIREMENT' named entity 'CHALLENGES' named entity 'DEVELOPMENTAL STAGES' named entity 'DEVELOPING COUNTRIES' named entity 'OF RISK' named entity 'RECOMBINANT' named entity 'FACTORIES' named entity 'VACCINES' named entity 'CURRENT' named entity 'PRODUCING' named entity 'PROTEIN PRODUCTION' named entity 'THESE' named entity 'INCLUDING' named entity 'MUCH' named entity 'OPTIMIZATION' named entity 'HUMAN' named entity 'MARKET' named entity 'SOURCES' named entity 'PARTS' named entity 'LARGE' named entity 'THERAPEUTICS' named entity 'IDENTIFIED' named entity 'PRODUCTS' named entity 'RECOMBINANT PROTEINS' named entity 'TRANSGENIC PLANTS' named entity 'CLINICAL' named entity 'POST-TRANSLATIONAL MODIFICATION' named entity 'ADVANCED' named entity 'VERY MUCH' named entity 'PHARMACEUTICAL INDUSTRY' named entity 'LIFE' named entity 'ENHANCING' named entity 'GREAT' named entity 'INTEREST' named entity 'REFLECT' named entity 'FLEXIBILITY' named entity 'PATHOGENIC' named entity 'SECTION' named entity 'FINDINGS' named entity 'SCALING' named entity 'NUMBER OF' named entity 'FUELED' named entity 'SOLUTION' named entity 'AIDS' named entity 'MOLECULAR FARMING' named entity 'FARMING' named entity 'CULTIVATION' named entity 'REVIEW' named entity 'SCALE' named entity 'STATUS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software